Clinical trials
Fallopian Tube Cancer clinical trials
Below are recruiting fallopian tube cancer clinical trials, each written for real people, not researchers. We’re tracking 104 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05287451Recruiting
Tube removal now, ovaries later for high cancer-risk women
This study looks at the safety of removing your fallopian tubes first (RRS) and delaying ovary removal (oophorectomy) to lower cancer risk. It focuses on women who carry certain inherited gene changes, and may help avoid earlier menopause for some people.
Chicago, IllinoisAges 18 years+ - NCT03983226RecruitingPhase 2
Surgery plus niraparib for returning ovarian cancer
This trial tests whether adding niraparib (a pill treatment that targets cancer cell DNA repair) after surgery can help people with ovarian cancer that has come back. It focuses on “platinum-sensitive” cases and tries to remove all visible tumor when possible.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05912972Recruiting
Registry study for women with gynecologic cancers
This is a research study that builds a registry (a record) of women in Korea with cervical, endometrial, or ovarian cancer. It may help researchers better understand these cancers and plan future studies.
SeoulAges 18 years+ - NCT05080556RecruitingPhase 2
Adaptive chemotherapy for ovarian cancer after platinum and PARP
This trial tests a personalized (adaptive) chemotherapy plan for people with certain types of ovarian/fallopian tube/peritoneal cancer who already had platinum chemotherapy and a PARP inhibitor. It’s for patients whose cancer came back after (or still responds to) prior platinum treatment and may help delay disease progression.
LondonAges 18 years+ - NCT07776691RecruitingPhase 3
Study of Raludotatug Deruxtecan for Advanced Ovarian Cancer
This study tests a new drug (raludotatug deruxtecan) with or without another drug (bevacizumab) as maintenance therapy after initial chemotherapy for advanced ovarian cancer. It aims to see if this combination can help keep the cancer from coming back.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06014190RecruitingPhase 2
HS-20089 for ovarian and endometrial cancer
This trial tests a new medication (HS-20089) for people with ovarian or endometrial cancer that has come back or spread. It aims to see if the drug can shrink tumors or slow cancer growth.
Hefei, AnfeiAges 18 years+ - NCT07708753RecruitingPhase 3
Study of a new drug for advanced ovarian cancer that stopped responding to platinum
This study tests a new drug called SYS6043 for advanced ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based chemotherapy. It aims to see if this drug can help when other treatments have not worked.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07665515RecruitingPhase 1
Testing a cancer vaccine in maintenance for advanced ovarian cancer
This trial tests a vaccine called CryptiVax-1001 for people with advanced ovarian cancer who have finished first-line chemotherapy and are in remission, as maintenance therapy. The goal is to see if the vaccine can help keep the cancer from coming back.
CambridgeAges 18 years+ - NCT07667192Recruiting
Re-treating gynecologic cancer with repeat radiation or ablation
This trial studies using additional radiation or tumor-destroying techniques for gynecologic cancer that has come back after previous radiation treatment. It helps doctors understand if this approach is safe and effective for women with recurrent disease.
Zamość, Lublin VoivodeshipAges 18 years+ - NCT07589543RecruitingPhase 1/Phase 2
CAR-NK Cell Therapy for Advanced Ovarian Cancer
This trial tests a new type of immune cell therapy (CAR-NK cells) designed to target and fight ovarian cancer that has returned or stopped responding to standard treatments. The therapy uses cells from your own body that have been modified in the lab to recognize and attack cancer cells.
Shenzhen, GuangdongAges 18–75 - NCT07586826RecruitingPhase 2
Romiplostim N01 plus ATRA for low platelets after cancer treatment
This trial tests a combination of two drugs (romiplostim N01 and ATRA) to help raise platelet counts in people whose platelets dropped after chemotherapy for gynecologic, breast, or lung cancer—even though their cancer is now gone. Low platelets can cause bleeding problems, so this treatment aims to help your body make more platelets.
BeijingAges 18 years+ - NCT06735326RecruitingPhase 2
Fluzoparib and Bevacizumab Before Surgery for Advanced Ovarian Cancer
This trial tests whether combining fluzoparib (a PARP inhibitor) with or without bevacizumab (a blood vessel growth blocker) before surgery can shrink advanced ovarian cancer. It is for women with a BRCA gene mutation whose cancer cannot be fully removed with surgery right now.
Jinan, ShandongAges 18 years+ - NCT07472140RecruitingPhase 2/Phase 3
PARP inhibitor with or without anti-angiogenesis drug for ovarian cancer
This trial tests whether adding a drug that blocks blood vessel growth (angiogenesis inhibitor) to a PARP inhibitor works better than the PARP inhibitor alone for ovarian, fallopian-tube, or peritoneal cancers that have a specific DNA repair problem called HRD. It aims to find a more effective treatment for people with these cancers.
Minsk, LesnoyAges 18–75 - NCT07460180RecruitingPhase 1/Phase 2
PARP inhibitor with chemo and HIPEC for ovarian cancer
This trial tests if adding a drug called a PARP inhibitor (which helps block cancer cells from repairing themselves) to standard chemotherapy and heated chemotherapy during surgery (HIPEC) can work better together for ovarian cancer that has already been treated with initial chemo. It is for people with a specific type of advanced ovarian cancer who are planning surgery after chemo.
AmsterdamAges 18–100 - NCT05200260RecruitingPhase 2
Surgery plus maintenance medicines for advanced ovarian cancer
This trial checks whether having surgery to remove as much tumor as possible, followed by ongoing targeted treatment, helps people with advanced ovarian (and related) cancers live longer and/or control cancer better. It specifically uses tumor-testing results to match patients and then continues treatment after surgery.
FoshanAges 18 years+ - NCT03976999Recruiting
Database study for ovarian, fallopian tube, and peritoneal cancers
This is a study that collects information and samples from people diagnosed with epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. It helps doctors better understand these cancers by building a clinical and biological database, which may improve care planning in the future.
MontpellierAges 18 years+ - NCT07402915RecruitingPhase 1
Study of AZD5335 with itraconazole in ovarian cancer
This study tests how the body handles the study drug AZD5335 when taken with itraconazole (a common antifungal). It is for people with platinum-resistant ovarian, primary peritoneal, or fallopian tube cancer who have already tried standard treatments.
BatumiAges 18 years+ - NCT00005095Recruiting
Ovarian cancer risk study: specimens and health data
This study collects tissue samples and medical information from people at higher risk for ovarian cancer or undergoing gynecologic surgery. Researchers use this data to develop better ways to detect and prevent ovarian cancer early.
Chicago, IllinoisAges 18–80 - NCT07322094RecruitingPhase 1/Phase 2
Study of TORL-1-23 plus chemo before surgery for advanced ovarian cancer
This trial tests a new drug, TORL-1-23, given with chemotherapy before surgery for women with advanced ovarian cancer. It aims to see if this combination is safe and effective in shrinking tumors before they are removed.
Fullerton, CaliforniaAges 18–75 - NCT07024784RecruitingPhase 2
Study of IMGN151 for gynecologic cancers
This study tests a new drug (IMGN151) given intravenously, alone or with other therapies, for people with certain gynecologic cancers, specifically high-grade serous ovarian, fallopian tube, or primary peritoneal cancer. The goal is to see how well it works and what side effects might occur.
Los Angeles, CaliforniaAges 18 years+ - NCT07023484RecruitingPhase 2
Timing of ovarian cancer surgery after chemo
This study looks at whether the timing of surgery after chemotherapy can be personalized for advanced ovarian cancer. It uses a blood test (CA125) to help decide the best time for surgery, aiming to improve outcomes.
GuangzhouAges 18 years+ - NCT07022535RecruitingPhase 2
Personalized timing of surgery for advanced ovarian cancer
This trial checks if adjusting the timing of surgery (interval debulking surgery) after chemotherapy can improve outcomes for people with advanced ovarian cancer. It's for those who cannot have surgery right away and will receive chemotherapy first.
Hong KongAges 18 years+ - NCT06994195RecruitingPhase 3
Comparing an experimental drug to standard chemo for ovarian cancer
This trial tests a new drug called BL-B01D1 against standard chemotherapy for people with ovarian cancer that no longer responds to platinum-based treatments. The goal is to see which option works better.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06969833Recruiting
Study of Ovarian, Peritoneal, or Fallopian Tube Cancer
This study will collect medical information from people with advanced ovarian, peritoneal, or fallopian tube cancer. The goal is to learn more about these cancers and improve future treatments.
LilleAges 18 years+
Hear when a new Fallopian Tube Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Fallopian Tube Cancer trials by city
Studies with a site in or near these metro areas.
Fallopian Tube Cancer trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for fallopian tube cancer?
- Yes. Clin2 currently lists 104 recruiting fallopian tube cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a fallopian tube cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a fallopian tube cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Stage IV Fallopian Tube Cancer AJCC v8
- Stage IVA Fallopian Tube Cancer AJCC v8
- Stage IVB Fallopian Tube Cancer AJCC v8
- Stage III Fallopian Tube Cancer
- Stage III Fallopian Tube Cancer AJCC v8
- Stage IIIC Fallopian Tube Cancer AJCC v8
- Stage IV Fallopian Tube Cancer
- Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.